RedHill Biopharma Ltd.(RDHL)Earnings, Financials & Key Ratios
RDHL•NASDAQ
$0.88
Price updated Jun 27, 2026
AboutRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Show more
- Revenue$8M+23.2%
- EBITDA-$14M-195.7%
- Net Income-$8M-134.6%
- EPS (Diluted)-7.00-115.2%
- Gross Margin60.31%+28.2%
- EBITDA Margin-173.99%-177.7%
- Operating Margin-181.69%-193.9%
- Net Margin-102.8%-128.1%
RDHL Price & Volume
RedHill Biopharma Ltd. (RDHL) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Corporate Solvency Sustainability
Investment Thesis • Updated 2025Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
"RedHill Biopharma faces a precarious financial outlook characterized by a severe erosion of equity to -$4.4 million and a persistent inability to scale commercial operations profitably. While the company has reported a 58.6% year-over-year revenue growth in recent quarters, this is insufficient to offset the $2.9 million quarterly SG&A burden that continues to drive deep operating losses. Investors should remain cautious as the company's liquidity buffer of $2.9 million appears inadequate to support ongoing operations without significant external capital, raising substantial concerns regarding long-term viability."
Verdict Logic
the company's inability to generate positive free cash flow, coupled with a $418 million accumulated deficit, suggests an imminent risk of further shareholder dilution or insolvency.
RDHL Growth Metrics
RedHill Biopharma Ltd. (RDHL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.38%
5 Years5.04%
3 Years-54.57%
TTM157.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM69.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.7%
Return on Capital
10 Years-33.82%
5 Years9.65%
3 Years95.91%
Last Year-
Peers Comparison
Key metrics vs top competitors for RedHill Biopharma Ltd. (RDHL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.88 | $4.49M | -0.13 | 23.17% | -102.8% | — | — | |
| $2.08 | $287.64M | -4.95 | -100% | — | -39.75% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $4.13 | $679.85M | 27.53 | -15.72% | 28.26% | — | — | |
| $46.84 | $2.7B | -68.88 | 8.63% | -3.74% | -2.73% | — | |
| $121.88 | $7.84B | -59.45 | -89.41% | -648.27% | -17.76% | — |
Compare RDHL vs Peers
RedHill Biopharma Ltd. (RDHL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RDHL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RDHL Frequently Asked Questions
RedHill Biopharma Ltd. (RDHL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is RedHill Biopharma Ltd.'s revenue?
RedHill Biopharma Ltd. (RDHL) reported $9.5M in revenue for fiscal year 2024. This represents a 41422% increase from $0.0M in 2011.
How fast is RedHill Biopharma Ltd. growing?
RedHill Biopharma Ltd. (RDHL) grew revenue by 23.2% over the past year. This is strong growth.
Is RDHL profitable?
RedHill Biopharma Ltd. (RDHL) reported a net loss of $9.3M for fiscal year 2024.
Dividend & Returns
What is RedHill Biopharma Ltd.'s free cash flow?
RedHill Biopharma Ltd. (RDHL) had negative free cash flow of $8.2M in fiscal year 2024, likely due to heavy capital investments.